Fetuin-A is an independent determinant of change of aortic stiffness over 1 year in non-diabetic patients with CKD stages 3 and 4

Nephrology Dialysis Transplantation

Volumn 25, Issue 6, 2010, Pages 1853-1858

  Ford, Martin L ^a   Tomlinson, Laurie A ^a   Smith, Edward R ^b   Rajkumar, Chakravarthi ^a   Holt, Stephen G ^a  

^a BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^b Brighton and Sussex University Hospitals   (United Kingdom)

Author keywords

Aortic stiffness; Blood pressure; Calcification inhibitor; Chronic kidney disease; Fetuin A

Indexed keywords

FETUIN A;

AGED; ARTERIAL STIFFNESS; ARTICLE; BLOOD VESSEL CALCIFICATION; CAROTID ARTERY PULSE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

AGED; AORTA; BLOOD PRESSURE; BLOOD PROTEINS; C-REACTIVE PROTEIN; CALCINOSIS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULSATILE FLOW; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; VASCULAR RESISTANCE;

EID: 77952972614     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp723     Document Type: Article

References (43)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
2. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305
3. Rao MV, Qiu Y, Wang C et al. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis 2008; 51: S30-S37 (Pubitemid 351444715)
4. Whaley-Connell AT, Sowers JR, McFarlane SI et al. Diabetes mel-litus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008; 51: S21-S29
5. Briet M, Bozec E, Laurent S et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006; 69: 350-357
6. Wang MC, Tsai WC, Chen JYet al. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am J Kidney Dis 2005; 45: 494-501
7. Avolio AP, Chen SG, Wang RP et al. Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation 1983; 68: 50-58
8. Safar ME, Frohlich ED. The arterial system in hypertension. A prospective view. Hypertension 1995; 26: 10-14
9. Lehmann ED, Gosling RG, Sonksen PH. Arterial wall compliance in diabetes. Diabet Med 1992; 9: 114-119
10. Benetos A, Adamopoulos C, Bureau JM et al. Determinants of accelerated progression of arterial stiffness in normotensive subjects and in treated hypertensive subjects over a 6-year period. Circulation 2002; 105: 1202-1207
11. Sigrist MK, Taal MW, Bungay P et al. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1241-1248
12. Laurent S, Cockcroft J, Van Bortel L et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605
13. Ketteler M, BongartzP, WestenfeldR etal. Associationoflow fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833
14. Ibels LS, Alfrey AC, Huffer WE et al. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66: 790-796
15. Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-223
16. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216
17. Heiss A, Eckert T, Aretz A et al. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J Biol Chem 2008; 283: 14815-14825
18. Schoppet M, Shroff RC, Hofbauer LC et al. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int 2008; 73: 384-390
19. Reynolds JL, Skepper JN, McNair R et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920-2930
20. Mathews ST, Chellam N, Srinivas PR et al. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol 2000; 164: 87-98
21. Ix JH, Shlipak MG, Brandenburg VM et al. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006; 113: 1760-1767
22. Stefan N, Fritsche A, Weikert C et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008; 57: 2762-2767
23. Mori K, Emoto M, Yokoyama H et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 2006; 29: 468
24. Moe SM, Reslerova M, Ketteler M et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67: 2295-2304
25. Burden R, Tomson C. Identification, management and referral of adults with chronic kidney disease: concise guidelines. Clin Med 2005; 5: 635-642
26. Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006; 7: 61-63
27. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470
28. Asmar R, Benetos A, Topouchian J et al. Assessment of arterial dis-tensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension 1995; 26: 485-490
29. Nichols WM ORM. McDonald's Blood Flow in Arteries. London: Hodder Arnold, 2005; 49-66, 70-93
30. Wang AY, Woo J, Lam CWet al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 1676-1685
31. Shroff RC, Shah V, Hiorns MP et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008; 23: 3263-3271
32. Hermans MM, Brandenburg V, Ketteler M et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006; 21: 1293-1299
33. Roos M, Richart T, Kouznetsova T et al. Fetuin-A and arterial stiffness in patients with normal kidney function. Regul Pept 2008
34. Ix JH, Shlipak MG, Sarnak MJ et al. Fetuin-A is not associated with mortality in chronic kidney disease. Kidney Int 2007; 72: 1394-1399
35. Casas JP, Shah T, Hingorani AD et al. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264: 295-314
36. Kessler M, Zannad F, Lehert P et al. Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in Dialysis study. Nephrol Dial Transplant 2007; 22: 3573-3579
37. Menon V, Greene T, Wang X et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-772
38. Lebreton JP, Joisel F, Raoult JP et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64: 1118-1129
39. Blacher J, Guerin AP, Pannier B et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439
40. Taal MW, Sigrist MK, Fakis A et al. Markers of arterial stiffness are risk factors for progression to end-stage renal disease among patients with chronic kidney disease stages 4 and 5. Nephron Clin Pract 2007; 107: c177-c181
41. Mori K, Emoto M, Araki T et al. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. Metabolism 2008; 57: 1248-1252
42. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
43. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with se-velamer increases serum fetuin-a concentration and improves endo-thelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68